Old Drugs, New Hope: Combo Reverses Fatty Liver in Animal Models

University of Barcelona researchers found that pairing two approved drugs, pemafibrate and telmisartan, reversed liver fat in MASLD animal models and may reduce cardiovascular risk; the duo was effective at half-doses together, suggesting synergy and safer therapy. Telmisartan appears to upregulate PCK1, shifting metabolism away from lipid synthesis. Human trials are still needed.